Financière de Tubize S.A.
TUB
Rang in aandelen
#2119
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Aandeelprijs
$217.90
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$9.70B
Verandering (1 dag)
5.57%
Verandering (1 jaar)
-19.89%
Land
BE
Handel Financière de Tubize S.A. (TUB)
Categorie
Healthcare
EPS voor Financière de Tubize S.A. (TUB)
EPS per June 2026 TTM: $2.62
Volgens de laatste financiële rapporten en de aandelenkoers van Financière de Tubize S.A. is de huidige EPS van het bedrijf (TTM) $2.62. Eind 2023 had het bedrijf een EPS van $2.19, een stijging ten opzichte van de EPS van 2022 die $2.05 bedroeg.
EPS-geschiedenis van Financière de Tubize S.A. van 2003 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $2.62 | 24.83% |
| 2024 | $2.10 | -3.97% |
| 2023 | $2.19 | 6.83% |
| 2022 | $2.05 | -4.16% |
| 2021 | $2.14 | -69.99% |
| 2020 | $7.12 | -25,913.77% |
| 2019 | $-0.03 | -100.37% |
| 2018 | $7.37 | -4.38% |
| 2017 | $7.70 | 79.89% |
| 2016 | $4.28 | -17.32% |
| 2015 | $5.18 | 214.76% |
| 2014 | $1.65 | -13.29% |
| 2013 | $1.90 | -17.32% |
| 2012 | $2.30 | 22.27% |
| 2011 | $1.88 | 198.71% |
| 2010 | $0.63 | -88.03% |
| 2009 | $5.25 | -18,644.17% |
| 2008 | $-0.03 | -102.18% |
| 2007 | $1.30 | -90.76% |
| 2006 | $14.08 | 80.81% |
| 2005 | $7.79 | 111.12% |
| 2004 | $3.69 | -20.63% |
| 2003 | $4.65 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | 560.72% |
US
|
|
| $-7.98 | -404.42% |
US
|
|
| $-5.29 | -301.80% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 958.21% |
NL
|
